Serina Therapeutics (NYSEAMERICAN:SER) Receives Buy Rating from BTIG Research

Serina Therapeutics (NYSEAMERICAN:SER)‘s stock had its “buy” rating reiterated by equities researchers at BTIG Research in a report issued on Thursday, Benzinga reports. They currently have a $8.00 target price on the stock. BTIG Research’s price objective suggests a potential upside of 230.58% from the company’s previous close.

Serina Therapeutics Stock Down 5.8%

Shares of NYSEAMERICAN SER traded down $0.15 during mid-day trading on Thursday, reaching $2.42. The company had a trading volume of 37,454 shares, compared to its average volume of 1,683,978. Serina Therapeutics has a 12-month low of $1.22 and a 12-month high of $5.83. The stock has a fifty day moving average of $2.36 and a two-hundred day moving average of $2.05. The company has a debt-to-equity ratio of 0.16, a quick ratio of 6.65 and a current ratio of 6.65. The company has a market capitalization of $61.47 million, a price-to-earnings ratio of -1.28 and a beta of 1.18.

Serina Therapeutics (NYSEAMERICAN:SER) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.55) earnings per share (EPS) for the quarter.

Serina Therapeutics Company Profile

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.